Purpose The first planned interim analysis (median follow-up, 3 years) of the Adjuvant
Chemotherapy Trial of S-1 for Gastric Cancer confirmed that the oral fluoropyrimidine …

Abstract Background The Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC)
demonstrated a survival benefit by adjuvant S-1 monotherapy in patients who had …

Background Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We
tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer …

Purpose The second planned interim analysis (median follow-up 12.5 months) in a phase III
trial of postoperative adjuvant chemotherapy for stage III gastric cancer revealed significant …

Background Postoperative adjuvant chemotherapy with S-1 for 1 year (corresponding to
eight courses) is standard care for stage II gastric cancer. Whether the duration of S-1 could …

4001 Background: Adjuvant chemotherapy and/or chemoradiotherapy have been the
standard of care in GC for years, supported by randomized trials. We compared the efficacy …

Background Adjuvant chemotherapy and chemoradiotherapy are some of the standards of
care for gastric cancer (GC). The Adjuvant chemoRadioTherapy In Stomach Tumors …

Background The prognosis for stage 3 gastric cancer is not satisfactory, even with S-1
adjuvant chemotherapy. A randomized phase II trial was conducted to compare two and four …

The current basic and clinical studies of S-1 (TS-1®) were reviewed. S-1 is a novel oral
dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a …

Background The aim of this study was to determine the efficacy of the EAP regimen
(etoposide, adriamycin and cisplatin) followed by the Machover schedule (fluorouracil and …